RESUMEN
Many reports have suggested that target-activated ribozymes hold potential value as detection reagents. We show that a "half"-ribozyme ligase is activated similarly by three unstructured oligoribonucleotides representing the major sequence variants of a hepatitis C virus 5'-untranslated region (5'-UTR) target and by a structured RNA corresponding to the entire 5'-UTR. Half-ribozyme ligation product was detected both in an ELISA-like assay and in an optical immunoassay through the use of hapten-carrying substrate RNAs. Both assay formats afford a limit of detection of approximately 1 x 10(6) HCV molecules (1.6 attomol, 330 fM), a sensitivity which compares favorably to that provided by standard immunoassays. These data suggest that target-activated ribozyme systems are a viable approach for the sensitive detection of viral nucleic acids using high-throughput platforms.
Asunto(s)
Hepatitis C/diagnóstico , ARN Catalítico/metabolismo , ARN Viral/análisis , Secuencia de Bases , Ensayo de Inmunoadsorción Enzimática/métodos , Hepatitis C/virología , Inmunoensayo/métodos , Cinética , Datos de Secuencia Molecular , Conformación de Ácido Nucleico , Sensibilidad y EspecificidadRESUMEN
Ribozymes are RNA or modified RNA polymers capable of catalyzing cleavage reactions in target strands RNA, and are under development as human therapeutics. Previous methods used for quantitation of nucleic acid polymers in serum or plasma required extraction of the polymer followed by capillary electrophoresis, HPLC, or gel electrophoresis. These methods are time consuming and lack sensitivity. A bioanalytical method has been developed that does not require extraction of the ribozyme analyte from serum. This technique relies on hybridization of the ribozyme molecule to two complementary biotin and digoxigenin labeled oligonucleotide probes. Serum containing the ribozyme is mixed with the labeled probes, and the mixture is heated at 75 degrees C for 5 min to disrupt the ribozyme secondary structure. Samples are then cooled to permit probe annealing and are added to a streptavidin-coated 96-well plate. The bound complex is detected with an anti-digoxigenin alkaline phosphatase (AP) conjugate using PNPP (p-nitrophenyl phosphate) as a substrate. The amount of colored product is measured on a microtiter plate reader at a wavelength of 405 nm. Concentrations of unknown ribozyme samples are estimated based on a standard curve (0.37-270 ng/ml) prepared in serum. The validated lower and upper limits of quantification are 5.0 and 120 ng/ml, respectively. The assay can be completed in approximately 5h and does not require extraction procedures or electrophoretic/chromatographic separation. It is therefore a simple, sensitive and rapid technique. This assay has been validated and has been used for quantitation of serum levels of the HEPTAZYME ribozyme in mouse, monkey, and human pharmacokinetic studies.
Asunto(s)
Hibridación de Ácido Nucleico/métodos , ARN Catalítico/sangre , ARN Catalítico/genética , Animales , Secuencia de Bases , Sitios de Unión/genética , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática/métodos , Ensayo de Inmunoadsorción Enzimática/normas , Femenino , Macaca fascicularis , Masculino , ARN Catalítico/farmacocinética , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: The recent emergence of avian H5N1 influenza virus has led to a growing concern regarding the potential for another influenza pandemic on the scale of the 1918 - 1919 outbreaks. Current influenza vaccines and therapies are effective against seasonal flu, but may prove inadequate in a flu pandemic due to influenza's propensity for rapid mutation and re-assortment. RNA interference (RNAi) therapies offer the potential of a new therapeutic approach, by targeting conserved regions of the influenza viral genome. OBJECTIVE: To evaluate RNAi as a potential mode of treatment for pandemic influenza. METHODS: The review describes current therapies and compares them to potential RNAi therapeutics, with emphasis on the potential hurdles facing RNAi therapeutics in the areas of drug design, delivery, treatment regimen and viral escape. CONCLUSIONS: RNAi therapeutics targeting > 95% of known influenza A sequences, including the avian H5N1 strains, have been shown to be highly effective in vitro. The challenge ahead will be to find effective delivery modalities that achieve the same high degree of effectiveness in human subjects and at an affordable cost. Viral escape will continue to be a concern until new RNAi therapeutics demonstrate that they can overcome, or at least minimize, this phenomenon.
Asunto(s)
Brotes de Enfermedades , Marcación de Gen/métodos , Virus de la Influenza A/genética , Gripe Humana/genética , ARN Interferente Pequeño/genética , Animales , Brotes de Enfermedades/prevención & control , Humanos , Virus de la Influenza A/inmunología , Vacunas contra la Influenza/administración & dosificación , Vacunas contra la Influenza/genética , Gripe Humana/prevención & control , ARN Interferente Pequeño/administración & dosificación , ARN Interferente Pequeño/químicaRESUMEN
To develop synthetic short interfering RNA (siRNA) molecules as therapeutic agents for systemic administration in vivo, chemical modifications were introduced into siRNAs targeted to conserved sites in hepatitis B virus (HBV) RNA. These modifications conferred significantly prolonged stability in human serum compared with unmodified siRNAs. Cell culture studies revealed a high degree of gene silencing after treatment with the chemically modified siRNAs. To assess activity of the stabilized siRNAs in vivo initially, an HBV vector-based model was used in which the siRNA and the HBV vector were codelivered via high-volume tail vein injection. More than a 3 log10 decrease in levels of serum HBV DNA and hepatitis B surface antigen, as well as liver HBV RNA, were observed in the siRNA-treated groups compared with the control siRNA-treated and saline groups. Furthermore, the observed decrease in serum HBV DNA was 1.5 log10 more with stabilized siRNA compared with unmodified siRNA, indicating the value of chemical modification in therapeutic applications of siRNA. In subsequent experiments, standard systemic intravenous dosing of stabilized siRNA 72 hours after injection of the HBV vector resulted a 0.9 log10 reduction of serum HBV DNA levels after 2 days of dosing. In conclusion, these experiments establish the strong impact that siRNAs can have on the extent of HBV infection and underscore the importance of stabilization of siRNA against nuclease degradation.
Asunto(s)
Virus de la Hepatitis B/fisiología , ARN Interferente Pequeño/fisiología , Replicación Viral/genética , Animales , Línea Celular Tumoral , Secuencia Conservada , ADN Viral/sangre , Dimerización , Relación Dosis-Respuesta a Droga , Estabilidad de Medicamentos , Silenciador del Gen , Marcación de Gen , Genoma Viral , Antígenos de Superficie de la Hepatitis B/sangre , Virus de la Hepatitis B/genética , Humanos , Ratones , ARN Interferente Pequeño/administración & dosificación , ARN Interferente Pequeño/síntesis química , ARN Interferente Pequeño/química , ARN Viral/sangreRESUMEN
We describe a strategy for the ultra-sensitive detection of nucleic acids using "half" ribozymes that are devoid of catalytic activity unless completed by a trans-acting target nucleic acid. The half-ribozyme concept was initially demonstrated using a construct derived from a multiple turnover Class I ligase. Iterative RNA selection was carried out to evolve this half-ribozyme into one activated by a conserved sequence present in the hepatitis C virus (HCV) genome. Following sequence optimization of substrate RNAs, this HCV-activated half-ribozyme displayed a maximal turnover rate of 69 min(-1) (pH 8.3) and was induced in rate by approximately 2.6 x 10(9)-fold by the HCV target. It detected the HCV target oligonucleotide in the zeptomole range (6700 molecules), a sensitivity of detection roughly 2.6 x 10(6)-fold greater than that previously demonstrated by oligonucleotide-activated ribozymes, and one that is sufficient for molecular diagnostic applications.